article Open AccessTop 1% cited
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Gynecologic Oncology · 2015 · Vol. 139(1) · pp. 10–16
Carol Aghajanian✉(Cornell University)Barbara A. Goff(University of Washington)Lawrence R. Nycum(Novant Health Forsyth Medical Center)Yan V. WangAmreen HusainStephanie V. Blank(New York University)
Ovarian cancer diagnosis and treatmentIntraperitoneal and Appendiceal MalignanciesViral-associated cancers and disordersMedicineBevacizumabOvarian cancerOncologyChemotherapyInternal medicineEpithelial ovarian cancerClinical trialCancer
MeSH terms
BevacizumabCarcinoma, Ovarian EpithelialGemcitabineAgedAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineFemaleHumansMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Glandular and EpithelialOvarian NeoplasmsSurvival RateCarboplatinDisease-Free Survival
Funding
- Genentech
Citations
310
FWCI
34.99
field-weighted impact
References
23
Percentile
100%
vs. same field & year
Citations per year
Cited by
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology · 2017 · 1,842 citations
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Annals of Oncology · 2019 · 1,130 citations
Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
Journal of Clinical Medicine · 2019 · 488 citations
References
Cancer statistics, 2015
CA A Cancer Journal for Clinicians · 2015 · 11,899 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.